Korean J Urol Oncol.
2017 Aug;15(2):59-65. 10.22465/kjuo.2017.15.2.59.
Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer
- Affiliations
-
- 1Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
- 2Department of Urology, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
- 3Department of Urology, Inje University Pusan Paik Hospital, Inje University College of Medicine, Busan, Korea. prosdoc@hanmail.net
- 4Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
- 5Department of Urology, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
- 6Department of Urology, Dong-A University College of Medicine, Busan, Korea.
- KMID: 2391194
- DOI: http://doi.org/10.22465/kjuo.2017.15.2.59
Abstract
- PURPOSE
This study compared the oncologic results of docetaxel chemotherapy (DOC) in castration-resistant prostate cancer (CRPC) according to continuous addition of androgen deprivation therapy (ADT) during chemotherapy.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 106 patients who received DOC in 6 medical institutes. Among them, 72 patients had a complete medical record: 28 patients with ADT (DOC+continuous ADT group) and 44 without ADT (DOC only group). We compared the progression-free survival of these groups after DOC.
RESULTS
Docetaxel was administered an average of 28 months after primary ADT as the first treatment. A median number of 6 cycles of DOC was administered in both groups. In the DOC+continuous ADT group, orchiectomy was performed in 18 patients and luteinizing hormone-releasing hormone agonist was injected in 10 patients. During DOC treatment, prostate-specific antigen (PSA) progression-free survival was statistically different (6.0±4.75 months in DOC+continuous ADT group vs. 4.8±3.2 months in DOC only group, p=0.024), whereas radiologic progression-free survival was not statistically different (5.0±3.12 months in DOC+continuous ADT group vs. 5.0±2.79 months in DOC only group, p=0.387).
CONCLUSIONS
In our cohort, continuous addition of ADT showed a significant benefit in PSA progression-free survival during DOC in CRPC patients. Further prospective studies are needed to confirm these observations.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer
- Hormonal therapy and chemotherapy for advanced prostate cancer
- Long-Lasting Antiandrogen Withdrawal Syndrome in Castration-Resistant Prostate Cancer: Three Cases With Complete Response
- Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
- Precision Medicine in Castration-Resistant Prostate Cancer
